Overview

Effect of Cequa™ in Subjects With Dry Eye Disease

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.

Phase:

Phase 4

Details

Lead Sponsor:

Sun Pharma Global FZE

Treatments:

Cyclosporine
Cyclosporins
Ophthalmic Solutions